Elanco Animal Health (ELAN) Total Non-Current Liabilities (2017 - 2026)

Elanco Animal Health (ELAN) reported Total Non-Current Liabilities of $6.3 billion for Q1 2026, up 2.52% on a YoY basis from $6.1 billion in Q1 2025, and down 3.87% sequentially from $6.5 billion in Q4 2025.

Elanco Animal Health (ELAN) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends

Elanco Animal Health (ELAN) has 10 years of Total Non-Current Liabilities data on file, last reported at $6.3 billion in Q1 2026.

  • For the quarter ending Q1 2026, Total Non-Current Liabilities rose 2.52% year-over-year to $6.3 billion; the trailing twelve-month figure through Mar 2026 stood at $6.3 billion (up 2.52% YoY), and the FY2025 full-year result was $6.5 billion, up 4.68% from the prior year.
  • Total Non-Current Liabilities fell to $6.3 billion in Q1 2026, from $6.5 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $8.4 billion in Q1 2022 to a low of -$193.0 million in Q2 2022.
  • A 5-year average of $6.7 billion and a median of $7.4 billion in 2024 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities tumbled 102.24% in 2022 and surged 4226.94% in 2023, its largest moves.
  • Tracing ELAN's Total Non-Current Liabilities over 5 years: stood at $8.0 billion in 2022, then decreased by 3.07% to $7.7 billion in 2023, then declined by 19.57% to $6.2 billion in 2024, then rose by 4.68% to $6.5 billion in 2025, then retreated by 3.87% to $6.3 billion in 2026.
  • Business Quant data shows ELAN's Total Non-Current Liabilities at $6.3 billion in Q1 2026, $6.5 billion in Q4 2025, and $6.2 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 599.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 6.26 Bn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn 604.70 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 6.26 Bn
Dec 31, 2025 6.51 Bn
Sep 30, 2025 6.20 Bn
Jun 30, 2025 6.33 Bn
Mar 31, 2025 6.10 Bn
Dec 31, 2024 6.22 Bn
Sep 30, 2024 6.17 Bn
Jun 30, 2024 7.36 Bn
Mar 31, 2024 7.49 Bn
Dec 31, 2023 7.73 Bn
Sep 30, 2023 7.78 Bn
Jun 30, 2023 7.97 Bn
Mar 31, 2023 8.04 Bn
Dec 31, 2022 7.97 Bn
Sep 30, 2022 7.98 Bn
Jun 30, 2022 -193.00 Mn
Mar 31, 2022 8.40 Bn
Dec 31, 2021 8.71 Bn
Sep 30, 2021 8.66 Bn
Jun 30, 2021 8.62 Bn